2026-07-21T16:29:03Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/154612024-11-29T08:14:04Zcom_20.500.12105_2052com_20.500.12105_2051com_20.500.12105_15322col_20.500.12105_19608col_20.500.12105_16968

00925njm 22002777a 4500 dc Sentís, Alexis author Kislaya, Irina author Nicolay, Nathalie author Meijerink, Hinta author Starrfelt, Jostein author Martínez-Baz, Iván author Castilla Catalán, Jesús author Nielsen, Katrine Finderup author Hansen, Christian Holm author Emborg, Hanne-Dorthe author Nardone, Anthony author Derrough, Tarik author Valenciano, Marta author Nunes, Baltazar author Monge, Susana author VEBIS-Lot4 working group author Larrauri, Amparo author Mazagatos, Clara author 2022-07 By employing a common protocol and data from electronic health registries in Denmark, Navarre (Spain), Norway and Portugal, we estimated vaccine effectiveness (VE) against hospitalisation due to COVID-19 in individuals aged ≥ 65 years old, without previous documented infection, between October 2021 and March 2022. VE was higher in 65-79-year-olds compared with ≥ 80-year-olds and in those who received a booster compared with those who were primary vaccinated. VE remained high (ca 80%) between ≥ 12 and < 24 weeks after the first booster administration, and after Omicron became dominant. Euro Surveill. 2022 Jul;27(30):2200551. 10.2807/1560-7917.ES.2022.27.30.2200551 1560-7917 Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin 35904059 http://hdl.handle.net/20.500.12105/15461 COVID-19 Delta variant Omicron variant Vaccination booster dose Vaccination primary course Vaccine effectiveness Estimation of COVID-19 vaccine effectiveness against hospitalisation in individuals aged ≥ 65 years using electronic health registries; a pilot study in four EU/EEA countries, October 2021 to March 2022